Separately, Zacks Investment Research raised ELEKTA AB/ADR from a hold rating to a buy rating and set a $14.00 price target for the company in a report on Wednesday, October 23rd.
EKTAY traded down $1.65 during midday trading on Thursday, hitting $13.11. 10,157 shares of the company traded hands, compared to its average volume of 4,753. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $5.63 billion, a PE ratio of 39.71, a price-to-earnings-growth ratio of 2.93 and a beta of 0.46. The company’s 50-day moving average is $13.32 and its 200 day moving average is $13.16. ELEKTA AB/ADR has a 52 week low of $10.95 and a 52 week high of $14.76.
Elekta AB (publ) provides equipment and software for cancer and brain disorders worldwide. The company offers radiotherapy systems under the Versa HD, Precise Treatment System, and Elekta Compact names; Elekta Infinity, an image-guided radiation therapy (IGRT) system; and Elekta Synergy, a digital accelerator for advanced IGRT.
Featured Article: How are Outstanding Shares Different from Authorized Shares?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ELEKTA AB/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ELEKTA AB/ADR and related companies with MarketBeat.com's FREE daily email newsletter.